Skip to main content

Akari Therapeutics Plc

corporate_fare Company Profile

Akari Therapeutics Plc

AKTX·NASDAQ·Life Sciences·CIK 0001541157

Akari is an oncology company that develops advanced antibody-drug conjugates (ADCs) designed to combat cancer. These ADCs are built using proprietary payloads that leverage powerful biological mechanisms. The company's primary payload, PH1, targets RNA splicing by modulating the spliceosome, a cellular mechanism essential for converting pre-RNA into spliced RNA, which is then translated into proteins vital for cell survival and growth. PH1 disrupts normal RNA splicing, leading to cancer cell death and cytotoxicity. Additionally, this disruption generates neoantigen proteins, which activate both the innate and adaptive immune systems, resulting in robust and lasting cancer-killing activity in preclinical models. AKTX-101 is active against urothelial cancers with FGFR3-fusions, lung cancers with SMARCA4 deletions and BRAF G466V mutations, and K-Ras G12V driven pancreatic cancers. The PH1 payload has also shown activity against metastatic prostate cancer cells driven by AR-v7 and AR-hormone dependent prostate cancer. Akari uses the PH1 payload as a platform to develop a pipeline of ADC candidates, each targeting a different cancer antigen, such as Trop-2 and CEACAM5. Akari's lead candidate, AKTX-101, targets the Trop-2 receptor on cancer cells. It is engineered with a proprietary linker to deliver the PH1 payload directly to tumors, minimizing off-target effects. Preclinical studies have shown AKTX-101 to have significant activity and prolonged survival in animal models compared to ADCs with traditional payloads (topoisomerase1 inhibitors). Due to PH1's unique ability to generate neoantigens, AKTX-101 may also be synergistic with checkpoint inhibitors, demonstrating prolonged survival in combination regimens that exceed the additive efficacy of either treatment alone. The company is advancing AKTX-101 towards clinical trials, having initiated IND-enabling studies with a goal of starting its First-In-Human Phase 1 trial by late 2026/early 2027.

Akari Therapeutics Plc (NASDAQ:AKTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for AKTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for AKTX spans 8-K, 10-Q, S-3/A, S-3.

Recent high-impact activity:

  • Akari Q3: $5.7M Cash, GLP Tox Started for AKTX-101, Phase 1 Targeted Mid-2027
  • Q3 Cash of $5.7M Leaves Akari With Runway Only Into Q1 2027
  • Akari 10-Q: Going-Concern Warning With $5.7M Cash and $24.1M Nine-Month Loss
  • Akari's AKTX-101 Shows Robust Anti-Tumor Activity in Preclinical Urothelial Cancer Models
  • Akari Therapeutics Q2 2026: Wider Loss, $7.7M Cash, Phase 1 Trial Set for Mid-2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$17.3M
Diluted EPS
$0.00
Op. Cash Flow
-$10.57M
Operating Income
-$17.27M
Cash & Equivalents
$0
Debt / Equity
0.00×
Shares Outstanding
90.54B sh
Source: 10-K · filed 2026-03-30 · accession 0001493152-26-013664

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 17,903 shares in AKTX as of the October 30, 2026 settlement, a 2.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 54.3% of AKTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,903 shares as of October 30, 2026
Change vs prior period▲ 2.1%
Days to cover1.00 at avg daily volume of 44,456
Daily short volume (FINRA facilities)54.3% of 4,624 shares on November 20, 2026
5-day average short volume49.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AKTX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-08.

1 shelf registration

Resale Registration Details · Deeply Discounted Warrants

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$6.71
52-week range · as of 2026-11-12 $3.02 – $29.32
Market cap
$15.33M
Volume
15.3K (0.4× avg)
3-mo avg 38.9K
Live data · 2026-11-21 01:45 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed AKTX - Latest Insights

AKTX
Nov 12, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.67
Real-time Price: $6.71 info
Change: +$0.040 (+0.60%) info
Market Cap: $15.333M info
AKTX
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $6.51
Real-time Price: $6.71 info
Change: +$0.200 (+3%) info
Market Cap: $15.333M info
AKTX
Nov 12, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $6.51
Real-time Price: $6.71 info
Change: +$0.200 (+3%) info
Market Cap: $15.333M info
AKTX
Aug 18, 2026, 8:56 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.79
Real-time Price: $6.71 info
Change: -$1.08 (-14%) info
Market Cap: $15.333M info
AKTX
Aug 13, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $6.71 info
Change: -$0.290 (-4%) info
Market Cap: $15.333M info
AKTX
Aug 13, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.00
Real-time Price: $6.71 info
Change: -$0.290 (-4%) info
Market Cap: $15.333M info
AKTX
Jul 08, 2026, 4:15 PM EDT
Filing Type: S-3/A
Importance Score:
9
Price at Filing: $14.21
Real-time Price: $6.71 info
Change: -$7.50 (-53%) info
Market Cap: $15.333M info
AKTX
Jul 02, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.41
Real-time Price: $6.71 info
Change: -$3.70 (-36%) info
Market Cap: $15.333M info
AKTX
Jul 02, 2026, 5:20 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $10.41
Real-time Price: $6.71 info
Change: -$3.70 (-36%) info
Market Cap: $15.333M info
AKTX
Jun 29, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $9.32
Real-time Price: $6.71 info
Change: -$2.61 (-28%) info
Market Cap: $15.333M info
AKTX
Jun 26, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.32
Real-time Price: $6.71 info
Change: -$2.61 (-28%) info
Market Cap: $15.333M info
AKTX
Jun 26, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.32
Real-time Price: $6.71 info
Change: -$2.61 (-28%) info
Market Cap: $15.333M info
AKTX
Jun 26, 2026, 5:00 PM EDT
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $10.73
Real-time Price: $6.71 info
Change: -$4.02 (-37%) info
Market Cap: $15.333M info
AKTX
Jun 04, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $15.85
Real-time Price: $6.71 info
Change: -$9.14 (-58%) info
Market Cap: $15.333M info
AKTX
May 22, 2026, 4:40 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $14.62
Real-time Price: $6.71 info
Change: -$7.91 (-54%) info
Market Cap: $15.333M info
AKTX
May 22, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $15.16
Real-time Price: $6.71 info
Change: -$8.45 (-56%) info
Market Cap: $15.333M info
AKTX
May 21, 2026, 5:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.84
Real-time Price: $6.71 info
Change: -$1.13 (-14%) info
Market Cap: $15.333M info
AKTX
May 21, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.18
Real-time Price: $6.71 info
Change: +$3.53 (+111%) info
Market Cap: $15.333M info
AKTX
May 19, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.74
Real-time Price: $6.71 info
Change: +$2.97 (+79%) info
Market Cap: $15.333M info
AKTX
May 12, 2026, 9:25 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.46
Real-time Price: $6.71 info
Change: +$1.25 (+23%) info
Market Cap: $15.333M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets